Eli Lilly Mounjaro Clocks 65% Jump in Sales to Massive $10.7 billion
Eli Lilly tops Q3 forecasts on surging Mounjaro sales, raises 2026 revenue outlook to $92 billion, and hits new 52-week highs despite an EPS forecast trim.
Share
Why It Matters
Eli Lilly's popular diabetes drug Mounjaro is selling really well. This shows the company is growing fast, so watch if they keep selling this much.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.